Why TOQidex Tracks These 13 Medical Conditions

TOQidex supports structured symptom tracking for 13 medical conditions. These were not chosen arbitrarily. They represent the intersection of three factors: population prevalence, frequency of medical cannabis use for the condition, and the availability of structured symptom frameworks for tracking.

Medical Cannabis by the Numbers

Over 6 million Americans are registered medical cannabis patients across 40+ legal states, with patient counts growing approximately 25% year-over-year (Marijuana Policy Project, 2025). In Canada, 161,267 patients are registered with licensed sellers, with an additional 11,304 registered for personal cultivation (Health Canada, March 2025).

A 2024 nationwide US survey published in Medical Cannabis and Cannabinoids found that the top reasons patients use medical cannabis are:

Source: Karger Publishers, Medical Cannabis and Cannabinoids, 2024

The 13 Conditions: Prevalence and Cannabis Research

Chronic Pain

24.3% of US adults report chronic pain, approximately 60 million people (CDC/NCHS Data Brief #518, 2024). The National Academies of Sciences (2017) found "substantial evidence" that cannabis is an effective treatment for chronic pain, making it one of the most evidence-supported use cases. In patient surveys, 98.4% of medical cannabis users report improvement in chronic pain symptoms (University of Florida / Medical Cannabis and Cannabinoids, 2024).

Anxiety

19.1% of US adults experience an anxiety disorder in any given year, with 31.1% affected over their lifetime (NIMH). It is the #1 reason people use medical cannabis, cited by 60.6% of patients. Patient-reported improvement rates reach 95.3%, with sustained improvements documented at 1, 3, and 6 months (NORML / UK Medical Cannabis Registry, 2024).

Depression

17.8% of US adults currently report depression, with 29% having a lifetime diagnosis (Gallup, 2023). Major depressive episodes affect 8.3% of adults, approximately 21 million people (NIMH, 2021). In patient surveys, 97.2% report improvement with medical cannabis (Medical Cannabis and Cannabinoids, 2024).

PTSD

3.6% of US adults experience PTSD in a given year, with 6% lifetime prevalence, approximately 13 million Americans (NIMH; VA National Center for PTSD). PTSD is cited by 34.8% of medical cannabis users. Research with nabilone (a synthetic cannabinoid) found 72% cessation or significant reduction in nightmares (PMC systematic review, 2021). However, 18.75% of patients in one study experienced symptom worsening, underscoring the importance of personal tracking.

Sleep Disorders

50-70 million Americans are affected by sleep disorders, with 12% diagnosed with chronic insomnia (AASM; Sleep Foundation). One-third of US adults report insufficient sleep (CDC). A Canadian retrospective review found 71% subjective improvement in sleep with medical cannabis, sustained at 18 months (PMC, 2022).

Fibromyalgia

2% of US adults, approximately 4 million people, are affected. 75-90% are women (CDC). The UK Medical Cannabis Registry documented sustained improvements in pain, anxiety, sleep, and quality of life at 1, 3, 6, 12, and 18 months (NORML, 2024).

Arthritis

21.2% of US adults, approximately 53.2 million people (CDC/NCHS Data Brief #497, 2024). Clinical trials have found 42-66% pain reduction, with 66% reporting improved physical function (NORML, 2024).

Multiple Sclerosis

Approximately 1 million Americans are affected, with 74% being female (National MS Society; JAMA Neurology, 2023). The National Academies of Sciences (2017) found "substantial evidence" for cannabinoid improvement of MS spasticity. Nabiximols (Sativex), a cannabis-derived pharmaceutical, has been approved for MS spasticity in several countries.

Menstrual Pain

71.3% of women of reproductive age experience dysmenorrhea globally (Systematic review, PubMed 2024). 84% of US women report moderate-to-severe cramps (Statista, 2023). Among women using cannabis for menstrual pain, 84% report significant relief (Journal of Women's Health, 2020).

Menopause

1.3 million US women enter menopause annually, with 80-90% experiencing problematic symptoms (SWHR/Menopause Journal). Among menopausal cannabis users, 78.7% report using it specifically for menopause symptoms, with sleep disturbances (67%) and mood/anxiety (46%) as the top targets (PMC, Alberta cross-sectional survey, 2023).

GI Issues (IBS/IBD)

25-45 million Americans have IBS. Approximately 2.39 million Americans have IBD (Crohn's & Colitis Foundation; ACG). Among IBD patients, 37-50% report lifetime cannabis use, with 94% considering it beneficial (PMC surveys). Important caveat: cannabis did not reduce inflammatory markers or achieve clinical remission in IBD in systematic reviews.

ADHD

6.0% of US adults, approximately 15.5 million people (CDC/NCHS, 2024). Among adults with ADHD, 42% report using cannabis specifically to manage symptoms (PubMed, 2025). The UK Medical Cannabis Registry documented significant quality of life improvement at months 1, 3, and 6, with a 38.5% reduction in concurrent ADHD medication use (PMC, 2023). Caveat: one randomized trial found cannabis may worsen inattention while improving impulsivity.

Alzheimer's Disease

6.9 million Americans age 65+ are affected, with prevalence reaching 33.4% among those 85+ (Alzheimer's Association, 2024). A Johns Hopkins/Tufts clinical trial found synthetic cannabis reduced agitation by 30% on average, with 79% of caregivers reporting effectiveness (2024). A separate study found CBD-rich oil achieved 30%+ reduction in agitation in 94% of participants (PubMed, 2025).

Why Tracking Matters More Than Averages

These statistics describe populations. Your experience is individual. The PTSD data shows 75%+ symptom reduction in some patients but 18.75% worsening in others. The anxiety data shows 95.3% improvement, but individual responses to specific products vary dramatically.

TOQidex exists because averages are not prescriptions. By tracking your personal response to measured product chemistry, you build an evidence base that is specific to you.